Tovorafenib's Joint Clinical Assessment Report: Comments by Cancer Patients Europe & the European Access Academy
16 June 2026 by Elaine JULIAN (EAA Faculty)The long-awaited first Joint Clinical Assessment (JCA) for Ipsen's Orphan Drug Tovorafenib (Ojemda ), indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have...